A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose

Exclusion Criteria

• •Significant medical history, psychiatric disorder, or acute infection at Screening (as determined by Investigator)
• •History of alcoholism or drug addiction within 6 months prior to CRU Check-in
• •Use of tobacco or nicotine-containing products from 6 months prior to CRU Check-in and during the study
• •Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred wtihin 30 days or 5 half-lives, whichever is longer, prior to CRU Check-in